Overview

Study of NS-9 in Patients With Liver Metastases

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is to investigate the safety of NS-9 and to see how well it is tolerated in patients with cancer that has metastasized (spread) to the liver from another primary tumor. NS-9 is a drug developed to go to the liver to cause cell death specifically in tumor cells. This study is also set up to determine the best dose to use.
Phase:
Phase 1
Details
Lead Sponsor:
NS Pharma, Inc.
Treatments:
Poly I-C